Minimal residual disease monitoring in acute myeloid leukaemia: are we ready to move from bone marrow to peripheral blood?

Br J Haematol. 2020 Jul;190(2):135-136. doi: 10.1111/bjh.16579. Epub 2020 Mar 19.

Authors

Michele Malagola^{1

2}, Simona Bernardi^{1

2

3}, Nicola Polverelli^{1

2}, Domenico Russo^{1

2}

Affiliations

¹ Chair of Hematology, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
² Unit of Blood Disease and Stem Cell Transplantation, ASST Spedali Civili of Brescia, Brescia, Italy.
³ CREA Laboratory (Hematological-Research AIL Centre), ASST-Spedali Civili Brescia, Brescia, Italy.

PMID: 32191348
DOI: 10.1111/bjh.16579

No abstract available

Publication types

Comment

MeSH terms

Bone Marrow
Child
Humans
Leukemia, Myeloid, Acute* / diagnosis
Myeloproliferative Disorders*
Neoplasm, Residual